Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Lancet
Diane M HarperHPV Vaccine Study group

Abstract

Effective vaccination against HPV 16 and HPV 18 to prevent cervical cancer will require a high level of sustained protection against infection and precancerous lesions. Our aim was to assess the long-term efficacy, immunogenicity, and safety of a bivalent HPV-16/18 L1 virus-like particle AS04 vaccine against incident and persistent infection with HPV 16 and HPV 18 and their associated cytological and histological outcomes. We did a follow-up study of our multicentre, double-blind, randomised, placebo-controlled trial reported in 2004. We included women who originally received all three doses of bivalent HPV-16/18 virus-like particle AS04 vaccine (0.5 mL; n=393) or placebo (n=383). We assessed HPV DNA, using cervical samples, and did yearly cervical cytology assessments. We also studied the long-term immunogenicity and safety of the vaccine. More than 98% seropositivity was maintained for HPV-16/18 antibodies during the extended follow-up phase. We noted significant vaccine efficacy against HPV-16 and HPV-18 endpoints: incident infection, 96.9% (95% CI 81.3-99.9); persistent infection: 6 month definition, 94.3 (63.2-99.9); 12 month definition, 100% (33.6-100). In a combined analysis of the initial efficacy and extended follow-up...Continue Reading

References

Aug 19, 1999·The Journal of Pathology·J M WalboomersN Muñoz
Feb 22, 2002·International Journal of Cancer. Journal International Du Cancer·Alba-Lucia CombitaPierre Coursaget
Mar 29, 2002·Journal of Clinical Pathology·F X BoschK V Shah
Apr 23, 2002·JAMA : the Journal of the American Medical Association·Thomas C WrightUNKNOWN ASCCP-Sponsored Consensus Conference
Nov 22, 2002·The New England Journal of Medicine·Laura A KoutskyUNKNOWN Proof of Principle Study Investigators
Feb 7, 2003·The New England Journal of Medicine·Nubia MuñozUNKNOWN International Agency for Research on Cancer Multicenter Cervical Cancer Study Group
Aug 15, 2003·International Journal of Cancer. Journal International Du Cancer·Sue J GoldieEduardo Franco
Jan 6, 2005·Vaccine·Sonia R Pagliusi, M Teresa Aguado
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
Apr 16, 2005·The Lancet Oncology·Vincent CoglianoUNKNOWN WHO International Agency for Research on Cancer
Dec 20, 2005·Best Practice & Research. Clinical Obstetrics & Gynaecology·R Sankaranarayanan, J Ferlay

❮ Previous
Next ❯

Citations

Sep 24, 2008·Archives of Internal Medicine·Natasha K StoutSue J Goldie
Nov 27, 2010·International Journal of Public Health·Nadia DemarteauBaudouin Standaert
Sep 18, 2009·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·Y Deleré
May 15, 2007·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·E Glastetter, A M Kaufmann
May 15, 2007·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·K U Petry
May 8, 2007·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·R Kirnbauer
Nov 11, 2006·Der Urologe. Ausg. A·P SchneedeE Hungerhuber
Jun 13, 2008·World Journal of Urology·Asif MuneerSuks Minhas
Jul 9, 2008·World Journal of Urology·M C G BleekerC J L M Meijer
Sep 5, 2009·Archives of Gynecology and Obstetrics·Chao-Hsiun TangChien-Jen Chen
Feb 24, 2007·Medical Microbiology and Immunology·Gerd Gross
Apr 30, 2013·Clinical Rheumatology·Mariele GattoYehuda Shoenfeld
May 29, 2009·Cancer Causes & Control : CCC·Richard A MooreAngela Brooks-Wilson
Oct 25, 2008·Journal of Community Health·Norma Martinez Rogers, Adelita G Cantu
Jan 4, 2008·Current Treatment Options in Oncology·Amy A HakimMark T Wakabayashi
Apr 24, 2009·Current Treatment Options in Oncology·Amy A Hakim, Tri A Dinh
Jul 11, 2009·Current HIV/AIDS Reports·Rachel H Gormley, Carrie L Kovarik
Jun 28, 2011·Current HIV/AIDS Reports·Carla J Chibwesha, Susan Cu-Uvin
Feb 28, 2007·Current Infectious Disease Reports·Alisa Ames, Patti Gravitt
Nov 10, 2006·Current Oncology Reports·Ali Mahdavi, Bradley J Monk
Oct 22, 2008·Current Oncology Reports·Carolyn D Runowicz, Stephanie Garozzo
Aug 15, 2012·Current Oncology Reports·Anne Szarewski
Jan 13, 2010·Immunologic Research·Ken LinT-C Wu
Apr 1, 2008·Journal of Biosciences·Cheryl M TravassoChandan Kumar-Sinha
Jun 28, 2007·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A González Martín
Dec 11, 2008·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Ana Oaknin, Ma Pilar Barretina
Aug 6, 2011·Advances in Therapy·Sherri N Sheinfeld GorinRebecca B Perkins
Mar 13, 2014·Journal of Crohn's & Colitis·J F RahierUNKNOWN European Crohn's and Colitis Organisation (ECCO)
Oct 18, 2008·Gastroentérologie Clinique Et Biologique·I Etienney, P Bauer
Jan 12, 2008·Journal de gynécologie, obstétrique et biologie de la reproduction·J-L Brun
Aug 28, 2012·The Lancet Infectious Diseases·Talía MalagónMarc Brisson
May 8, 2009·Immunology and Cell Biology·Balasubramanyam KaranamRichard B S Roden
Jan 29, 2008·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Kuan-Ting KuoMing-Chieh Lin
Nov 10, 2006·Nature Biotechnology·Jeffrey B UlmerRino Rappuoli
Oct 11, 2007·Nature Clinical Practice. Oncology·Chris J L M MeijerPeter J F Snijders
May 5, 2007·Nature Medicine·Holger KanzlerRobert L Coffman
Sep 23, 2006·Nature Reviews. Cancer·Richard Roden, T-C Wu
Nov 17, 2006·Nature Reviews. Cancer·Lauren M F MerloCarlo C Maley
Jul 2, 2010·Nature Reviews. Cancer·Cary A Moody, Laimonis A Laimins
Jul 4, 2006·Nature Reviews. Drug Discovery·Grzegorz NalepaJ Wade Harper
Feb 20, 2013·Nature Reviews. Gastroenterology & Hepatology·Javier P Gisbert, María Chaparro

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.